JP2017514843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514843A5 JP2017514843A5 JP2016565482A JP2016565482A JP2017514843A5 JP 2017514843 A5 JP2017514843 A5 JP 2017514843A5 JP 2016565482 A JP2016565482 A JP 2016565482A JP 2016565482 A JP2016565482 A JP 2016565482A JP 2017514843 A5 JP2017514843 A5 JP 2017514843A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- liquid crystalline
- delivery system
- crystalline drug
- api
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 23
- 238000012377 drug delivery Methods 0.000 claims 20
- 239000008186 active pharmaceutical agent Substances 0.000 claims 16
- 208000030533 eye disease Diseases 0.000 claims 12
- 239000000243 solution Substances 0.000 claims 10
- 239000006185 dispersion Substances 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 229920001451 polypropylene glycol Polymers 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 229920001477 hydrophilic polymer Polymers 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 230000003232 mucoadhesive effect Effects 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000004359 castor oil Substances 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960004875 difluprednate Drugs 0.000 claims 3
- 229960000289 fluticasone propionate Drugs 0.000 claims 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960003702 moxifloxacin Drugs 0.000 claims 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 229920001503 Glucan Polymers 0.000 claims 2
- 229920002907 Guar gum Polymers 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
- 240000004584 Tamarindus indica Species 0.000 claims 2
- 235000004298 Tamarindus indica Nutrition 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 229960004099 azithromycin Drugs 0.000 claims 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 2
- 150000007980 azole derivatives Chemical class 0.000 claims 2
- 229940092705 beclomethasone Drugs 0.000 claims 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 208000010217 blepharitis Diseases 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 229960004544 cortisone Drugs 0.000 claims 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960001048 fluorometholone Drugs 0.000 claims 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 2
- 229960001469 fluticasone furoate Drugs 0.000 claims 2
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 239000000665 guar gum Substances 0.000 claims 2
- 235000010417 guar gum Nutrition 0.000 claims 2
- 229960002154 guar gum Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 229960003744 loteprednol etabonate Drugs 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229960001002 nepafenac Drugs 0.000 claims 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 229940044476 poloxamer 407 Drugs 0.000 claims 2
- 229920001992 poloxamer 407 Polymers 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229950005134 polycarbophil Drugs 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229960001589 posaconazole Drugs 0.000 claims 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 229960002800 prednisolone acetate Drugs 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229960004224 tyloxapol Drugs 0.000 claims 2
- 229920001664 tyloxapol Polymers 0.000 claims 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 229960001777 castor oil Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 229960001798 loteprednol Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960000808 netilmicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- -1 polycarbopol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960001487 rimexolone Drugs 0.000 claims 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987012P | 2014-05-01 | 2014-05-01 | |
| US61/987,012 | 2014-05-01 | ||
| PCT/US2015/028748 WO2015168523A1 (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514843A JP2017514843A (ja) | 2017-06-08 |
| JP2017514843A5 true JP2017514843A5 (https=) | 2017-12-14 |
| JP6452725B2 JP6452725B2 (ja) | 2019-01-16 |
Family
ID=54359368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565482A Active JP6452725B2 (ja) | 2014-05-01 | 2015-05-01 | 眼疾患の治療のための膜付着性の自己組織化システム |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9901544B2 (https=) |
| EP (1) | EP3137481B1 (https=) |
| JP (1) | JP6452725B2 (https=) |
| KR (1) | KR101890503B1 (https=) |
| CN (1) | CN106459137B (https=) |
| AU (2) | AU2015252908B2 (https=) |
| CA (1) | CA2946373C (https=) |
| ES (1) | ES2924768T3 (https=) |
| MY (1) | MY193694A (https=) |
| NZ (1) | NZ725028A (https=) |
| SG (1) | SG11201608729RA (https=) |
| WO (1) | WO2015168523A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3266446B1 (en) * | 2016-07-07 | 2018-11-21 | Laboratorios SALVAT, S.A. | Ophthalmic composition comprising castor oil and medium chain triglyceride |
| US20200121652A1 (en) * | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| EP3639854B1 (en) | 2017-06-16 | 2026-01-07 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy |
| KR102115285B1 (ko) * | 2017-06-22 | 2020-05-26 | 연성정밀화학(주) | 녹내장 치료용 점안 조성물 |
| US11129862B2 (en) * | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
| CN111225687A (zh) * | 2017-09-01 | 2020-06-02 | 默里和普尔企业有限公司 | 用于治疗眼科疾患的方法和组合物 |
| JP7056480B2 (ja) * | 2017-09-08 | 2022-04-19 | ライオン株式会社 | 眼科用組成物及び涙液油層安定化剤 |
| CN109316440B (zh) * | 2018-09-29 | 2020-12-29 | 华中科技大学 | 一种温敏性液晶纳米水凝胶及其制备方法与应用 |
| CN113271979A (zh) | 2018-10-24 | 2021-08-17 | 费灵有限公司 | 皮质类固醇的粘膜粘附性药物组合物 |
| GB201818043D0 (en) * | 2018-11-05 | 2018-12-19 | Waterford Institute Of Tech | Artifical Tears |
| MX2022014459A (es) * | 2020-05-18 | 2023-02-27 | Max Biology Co Ltd | Composiciones de lipidos y polimeros y metodos de uso. |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| US12016855B2 (en) | 2020-08-26 | 2024-06-25 | Somerset Therapeutics, Llc | Prednisolone and moxifloxacin compositions and methods |
| WO2022077060A1 (en) * | 2020-10-13 | 2022-04-21 | University Of South Australia | Antimicrobial compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP4049216B2 (ja) * | 2003-05-09 | 2008-02-20 | ポーラ化成工業株式会社 | 液晶構造を有する製剤 |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20050235740A1 (en) * | 2004-04-27 | 2005-10-27 | Guido Desie | Method to improve the quality of dispersion formulations |
| CA2578709C (en) * | 2004-06-17 | 2010-06-15 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| WO2006062875A1 (en) * | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| US8906392B2 (en) * | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| JP2010064995A (ja) * | 2008-09-12 | 2010-03-25 | Nikko Chemical Co Ltd | 外用消炎鎮痛剤組成物 |
| JP5207420B2 (ja) * | 2009-12-25 | 2013-06-12 | 株式会社ケムジェネシス | 低粘度液晶化合物 |
| CN101773670A (zh) * | 2009-12-29 | 2010-07-14 | 中山大学 | 一种液晶药物载体 |
| JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
| US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
| NZ742005A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| AU2013259872B2 (en) * | 2012-05-08 | 2018-06-28 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
-
2015
- 2015-05-01 SG SG11201608729RA patent/SG11201608729RA/en unknown
- 2015-05-01 CN CN201580019868.9A patent/CN106459137B/zh active Active
- 2015-05-01 WO PCT/US2015/028748 patent/WO2015168523A1/en not_active Ceased
- 2015-05-01 KR KR1020167030513A patent/KR101890503B1/ko active Active
- 2015-05-01 EP EP15785661.8A patent/EP3137481B1/en active Active
- 2015-05-01 CA CA2946373A patent/CA2946373C/en active Active
- 2015-05-01 MY MYPI2016703941A patent/MY193694A/en unknown
- 2015-05-01 US US15/308,000 patent/US9901544B2/en active Active
- 2015-05-01 JP JP2016565482A patent/JP6452725B2/ja active Active
- 2015-05-01 NZ NZ725028A patent/NZ725028A/en unknown
- 2015-05-01 AU AU2015252908A patent/AU2015252908B2/en active Active
- 2015-05-01 ES ES15785661T patent/ES2924768T3/es active Active
-
2018
- 2018-02-27 US US15/906,352 patent/US10603273B2/en active Active
- 2018-03-06 AU AU2018201596A patent/AU2018201596B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514843A5 (https=) | ||
| US20250049719A1 (en) | Dexamethasone prodrug compositions and uses thereof | |
| JP6452725B2 (ja) | 眼疾患の治療のための膜付着性の自己組織化システム | |
| RU2747803C2 (ru) | Водная суспензия, содержащая наночастицы глюкокортикостероида | |
| CN107582605A (zh) | 眼用组合物 | |
| CN107205929B (zh) | 多泡沫体及其眼睑施用 | |
| CN101757621B (zh) | 一种眼部抗炎的环糊精包合药物组合物 | |
| TWI620578B (zh) | 用以減少眼用類固醇的倂發症之藥學組成物 | |
| CN101657184A (zh) | 用于眼用的基于非极性和极性脂质的药物制剂 | |
| JP2015526467A5 (https=) | ||
| JP2015506983A5 (https=) | ||
| JP6861634B2 (ja) | 眼疾患を処置するための組成物及び方法 | |
| JP2017501184A (ja) | 低減された眼圧で術後の炎症を治療するための方法 | |
| JP2006225323A (ja) | 水性外用組成物 | |
| CN109984995A (zh) | 一种伊维菌素纳米乳注射液及其制备方法 | |
| WO2025144421A1 (en) | Aqueous nanomicelle ophthalmic formulations containing difluprednate | |
| WO2017007609A1 (en) | Ocular treatment with reduced intraocular pressure | |
| EP3851097A1 (en) | Controlled release formulations | |
| HK1234413B (zh) | 用於治療眼部病症的膜附著性自組裝體系 | |
| HK1234413A1 (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders |